Aclaris Therapeutics Announces Preclinical Results From Potent And Selective ITK/JAK3 Inhibitor ATI-2138 In Murine Model Of Severe Alopecia Areata
Benzinga Newsdesk 9 months ago
News
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype -WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype -
WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine model of severe alopecia areata (AA). In this model of hair loss, conducted by Dr. Angela Christiano at Columbia University, ATI-2138 demonstrated rapid, near complete, and sustained hair regrowth compared to control and ritlecitinib.